Biosynex takes up residence in Delémont The French company Biosynex develops analytical, diagnostic and prophylactic medical devices. Its portfolio includes a test for Covid-19. It has…annett03.01.2021
Novartis Campus opening further Novartis' 25-year anniversary also marks the next step in the ongoing opening of the campus. The Switzerland Innovation Park Basel…annett02.25.2021
Hemex attracts Swiss investors A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The…martin02.11.2021
Rhizen drug secures approval in the USA The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered…martin02.10.2021
Novaremed secures US$50 million Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to…martin02.03.2021
Axtria driving growth from Basel The US firm Axtria has established a new office in Basel. The company offers services for the life sciences industry…martin02.01.2021
Technologiepark Basel celebrates its role as a driver of innovation The Technologiepark Basel will be ten years old in 2021. Over the past decade, it has supported many startups and…martin01.28.2021
Basel Area has ever more to offer investors The canton of Basel-Stadt has displayed the most striking performance in the Swiss Venture Capital Report. Last year, more than…martin01.28.2021
Basel researchers developing universal cancer therapy Researchers from Basel are working on the development of a therapy in which pre-prepared immune cells can be used to…martin01.26.2021
Opterion Health AG moving to Muttenz Opterion is moving from the canton of Obwalden to Muttenz in the canton of Basel-Landschaft in order to benefit from…martin01.22.2021